Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Andreas H. Scheel, Gudrun Baenfer, Gustavo Baretton, Manfred Dietel, Rolf Diezko, Thomas Henkel, Lukas C. Heukamp, Bharat Jasani, Korinna Jöhrens, Thomas Kirchner, Felix Lasitschka, Iver Petersen, Simone Reu, Hans Ulrich Schildhaus, Peter Schirmacher, Kristina Schwamborn, Ulrich Sommer, Oliver Stoss, Markus Tiemann, Arne Warth & 4 others Wilko Weichert, Jürgen Wolf, Reinhard Büttner, Josef Rüschoff

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: Programmed death ligand 1 (PD-L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD-L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory-developed tests (LDTs) at 10 German testing sites. Methods and results: To assess interlaboratory concordance, a tissue microarray containing 21 pulmonary carcinoma specimens was centrally prepared. Pre-cut sections were stained at 10 sites by the use of assays 28-8, 22C3, SP263, and SP142, as well as 11 LDTs. Assay performance was evaluated with a second tissue microarray containing 11 cell lines with defined PD-L1 expression. Quality control was centrally performed by manual and digital analyses. The assays yielded reproducible IHC staining patterns at all sites. In agreement with previous studies, 22C3, 28-8 and SP263 showed similar staining patterns, whereas SP142 was distinct. Among the LDTs, six of 11 protocols showed staining patterns similar to those of assays 22C3 and 28-8. Interlaboratory concordance of tumour cell scoring by use of a six-step system was moderate (Light's κ = 0.43–0.69), whereas the clinically approved cut-offs of ≥1% and ≥50% showed substantial concordance (κ = 0.73–0.89). Immune cell scoring by the use of SP142 yielded moderate concordance (κ = 0.42). Conclusions: The data confirm the previously described staining patterns of the assays, and show that they can be reproducibly employed at different sites. LDTs with staining results similar to those of the assays are implementable, but have to be carefully validated.

Original languageEnglish
Pages (from-to)449-459
Number of pages11
JournalHistopathology
Volume72
Issue number3
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Immunohistochemistry
Staining and Labeling
Ligands
Routine Diagnostic Tests
Quality Control
Lung Neoplasms
Clinical Trials
Carcinoma
Cell Line
Lung
Research
Neoplasms
Therapeutics

Keywords

  • CD274 antigens
  • immunohistochemistry
  • immunotherapy
  • non-small-cell lung carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Scheel, A. H., Baenfer, G., Baretton, G., Dietel, M., Diezko, R., Henkel, T., ... Rüschoff, J. (2018). Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology, 72(3), 449-459. https://doi.org/10.1111/his.13375

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. / Scheel, Andreas H.; Baenfer, Gudrun; Baretton, Gustavo; Dietel, Manfred; Diezko, Rolf; Henkel, Thomas; Heukamp, Lukas C.; Jasani, Bharat; Jöhrens, Korinna; Kirchner, Thomas; Lasitschka, Felix; Petersen, Iver; Reu, Simone; Schildhaus, Hans Ulrich; Schirmacher, Peter; Schwamborn, Kristina; Sommer, Ulrich; Stoss, Oliver; Tiemann, Markus; Warth, Arne; Weichert, Wilko; Wolf, Jürgen; Büttner, Reinhard; Rüschoff, Josef.

In: Histopathology, Vol. 72, No. 3, 01.02.2018, p. 449-459.

Research output: Contribution to journalArticle

Scheel, AH, Baenfer, G, Baretton, G, Dietel, M, Diezko, R, Henkel, T, Heukamp, LC, Jasani, B, Jöhrens, K, Kirchner, T, Lasitschka, F, Petersen, I, Reu, S, Schildhaus, HU, Schirmacher, P, Schwamborn, K, Sommer, U, Stoss, O, Tiemann, M, Warth, A, Weichert, W, Wolf, J, Büttner, R & Rüschoff, J 2018, 'Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer', Histopathology, vol. 72, no. 3, pp. 449-459. https://doi.org/10.1111/his.13375
Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology. 2018 Feb 1;72(3):449-459. https://doi.org/10.1111/his.13375
Scheel, Andreas H. ; Baenfer, Gudrun ; Baretton, Gustavo ; Dietel, Manfred ; Diezko, Rolf ; Henkel, Thomas ; Heukamp, Lukas C. ; Jasani, Bharat ; Jöhrens, Korinna ; Kirchner, Thomas ; Lasitschka, Felix ; Petersen, Iver ; Reu, Simone ; Schildhaus, Hans Ulrich ; Schirmacher, Peter ; Schwamborn, Kristina ; Sommer, Ulrich ; Stoss, Oliver ; Tiemann, Markus ; Warth, Arne ; Weichert, Wilko ; Wolf, Jürgen ; Büttner, Reinhard ; Rüschoff, Josef. / Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. In: Histopathology. 2018 ; Vol. 72, No. 3. pp. 449-459.
@article{d1ca88baac9047a69107d2d9e3c22d3f,
title = "Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer",
abstract = "Aims: Programmed death ligand 1 (PD-L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD-L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory-developed tests (LDTs) at 10 German testing sites. Methods and results: To assess interlaboratory concordance, a tissue microarray containing 21 pulmonary carcinoma specimens was centrally prepared. Pre-cut sections were stained at 10 sites by the use of assays 28-8, 22C3, SP263, and SP142, as well as 11 LDTs. Assay performance was evaluated with a second tissue microarray containing 11 cell lines with defined PD-L1 expression. Quality control was centrally performed by manual and digital analyses. The assays yielded reproducible IHC staining patterns at all sites. In agreement with previous studies, 22C3, 28-8 and SP263 showed similar staining patterns, whereas SP142 was distinct. Among the LDTs, six of 11 protocols showed staining patterns similar to those of assays 22C3 and 28-8. Interlaboratory concordance of tumour cell scoring by use of a six-step system was moderate (Light's κ = 0.43–0.69), whereas the clinically approved cut-offs of ≥1{\%} and ≥50{\%} showed substantial concordance (κ = 0.73–0.89). Immune cell scoring by the use of SP142 yielded moderate concordance (κ = 0.42). Conclusions: The data confirm the previously described staining patterns of the assays, and show that they can be reproducibly employed at different sites. LDTs with staining results similar to those of the assays are implementable, but have to be carefully validated.",
keywords = "CD274 antigens, immunohistochemistry, immunotherapy, non-small-cell lung carcinoma",
author = "Scheel, {Andreas H.} and Gudrun Baenfer and Gustavo Baretton and Manfred Dietel and Rolf Diezko and Thomas Henkel and Heukamp, {Lukas C.} and Bharat Jasani and Korinna J{\"o}hrens and Thomas Kirchner and Felix Lasitschka and Iver Petersen and Simone Reu and Schildhaus, {Hans Ulrich} and Peter Schirmacher and Kristina Schwamborn and Ulrich Sommer and Oliver Stoss and Markus Tiemann and Arne Warth and Wilko Weichert and J{\"u}rgen Wolf and Reinhard B{\"u}ttner and Josef R{\"u}schoff",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/his.13375",
language = "English",
volume = "72",
pages = "449--459",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley Blackwell",
number = "3",

}

TY - JOUR

T1 - Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

AU - Scheel, Andreas H.

AU - Baenfer, Gudrun

AU - Baretton, Gustavo

AU - Dietel, Manfred

AU - Diezko, Rolf

AU - Henkel, Thomas

AU - Heukamp, Lukas C.

AU - Jasani, Bharat

AU - Jöhrens, Korinna

AU - Kirchner, Thomas

AU - Lasitschka, Felix

AU - Petersen, Iver

AU - Reu, Simone

AU - Schildhaus, Hans Ulrich

AU - Schirmacher, Peter

AU - Schwamborn, Kristina

AU - Sommer, Ulrich

AU - Stoss, Oliver

AU - Tiemann, Markus

AU - Warth, Arne

AU - Weichert, Wilko

AU - Wolf, Jürgen

AU - Büttner, Reinhard

AU - Rüschoff, Josef

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Aims: Programmed death ligand 1 (PD-L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD-L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory-developed tests (LDTs) at 10 German testing sites. Methods and results: To assess interlaboratory concordance, a tissue microarray containing 21 pulmonary carcinoma specimens was centrally prepared. Pre-cut sections were stained at 10 sites by the use of assays 28-8, 22C3, SP263, and SP142, as well as 11 LDTs. Assay performance was evaluated with a second tissue microarray containing 11 cell lines with defined PD-L1 expression. Quality control was centrally performed by manual and digital analyses. The assays yielded reproducible IHC staining patterns at all sites. In agreement with previous studies, 22C3, 28-8 and SP263 showed similar staining patterns, whereas SP142 was distinct. Among the LDTs, six of 11 protocols showed staining patterns similar to those of assays 22C3 and 28-8. Interlaboratory concordance of tumour cell scoring by use of a six-step system was moderate (Light's κ = 0.43–0.69), whereas the clinically approved cut-offs of ≥1% and ≥50% showed substantial concordance (κ = 0.73–0.89). Immune cell scoring by the use of SP142 yielded moderate concordance (κ = 0.42). Conclusions: The data confirm the previously described staining patterns of the assays, and show that they can be reproducibly employed at different sites. LDTs with staining results similar to those of the assays are implementable, but have to be carefully validated.

AB - Aims: Programmed death ligand 1 (PD-L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD-L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory-developed tests (LDTs) at 10 German testing sites. Methods and results: To assess interlaboratory concordance, a tissue microarray containing 21 pulmonary carcinoma specimens was centrally prepared. Pre-cut sections were stained at 10 sites by the use of assays 28-8, 22C3, SP263, and SP142, as well as 11 LDTs. Assay performance was evaluated with a second tissue microarray containing 11 cell lines with defined PD-L1 expression. Quality control was centrally performed by manual and digital analyses. The assays yielded reproducible IHC staining patterns at all sites. In agreement with previous studies, 22C3, 28-8 and SP263 showed similar staining patterns, whereas SP142 was distinct. Among the LDTs, six of 11 protocols showed staining patterns similar to those of assays 22C3 and 28-8. Interlaboratory concordance of tumour cell scoring by use of a six-step system was moderate (Light's κ = 0.43–0.69), whereas the clinically approved cut-offs of ≥1% and ≥50% showed substantial concordance (κ = 0.73–0.89). Immune cell scoring by the use of SP142 yielded moderate concordance (κ = 0.42). Conclusions: The data confirm the previously described staining patterns of the assays, and show that they can be reproducibly employed at different sites. LDTs with staining results similar to those of the assays are implementable, but have to be carefully validated.

KW - CD274 antigens

KW - immunohistochemistry

KW - immunotherapy

KW - non-small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85034619177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034619177&partnerID=8YFLogxK

U2 - 10.1111/his.13375

DO - 10.1111/his.13375

M3 - Article

VL - 72

SP - 449

EP - 459

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -